Dave Ennis

Vice President of Chemical Development, AstraZeneca

He has technical accountability for all aspects of Chemical Development input to projects, including; route and process design; optimization and control strategy development; generation of approval regulatory submissions; and technical support and improvement of commercial manufacturing processes throughout their lifecycle. During this time he has been involved in development & commercialization of 16 New Chemical Entities.

Dave has a passion for enhancing capabilities in design of flexible, robust, cost effective and sustainable processes and in building new capabilities to address the challenges of a diverse pipeline of molecules and new modalities.

Dave completed his undergraduate training at the University of Liverpool where he achieved a 1st class degree in Chemistry, followed by doctoral training at the University of Liverpool, obtaining his PhD in Organic Chemistry in 1990. This was followed by Postdoctoral work at Yale University in the laboratories of Professor Harry Wasserman, before starting his industrial career in 1993 at SmithKline Beecham. He joined AstraZeneca in 1998 where he has held a series of leadership roles and has been in his present position since 2013